144. J Oncol Pharm Pract. 2018 Jan 1:1078155218790179. doi: 10.1177/1078155218790179. [Epub ahead of print]Retraction notice.[No authors listed]At the request of the Editors, SAGE Publishing and the Authors, the followingarticle has been retracted. Cost-utility analysis of trastuzumab combined withDocetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data, Henry WC Leung, Agnes LF Chan, Shyh-Yau Wang, Journal of OncologyPharmacy Practice, first published online January 31st 2018 DOI:10.1177/1078155218755548 The authors notified the Editor and SAGE that some ofthe data included in this paper is incorrect and therefore results may beunreliable. For this reason, the article has been retracted. The authors of this paper are currently reviewing their data and the journal welcomes the authors to submit a new paper with revised, corrected data for consideration.DOI: 10.1177/1078155218790179 PMID: 29986625 